Search results
Your search for process/pmg6 returned no results
Showing 2611 to 2625 of 2854 results for process
Showing 2611 to 2625 of 2854 results for process
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Discontinued Reference number: GID-TA10764
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued Reference number: GID-TA10065
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)
NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system
Contrast-enhanced spectral mammography for breast cancer (MIB304)
NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .
NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .
Stretta System for gastro-oesophageal reflux disease (MIB74)
NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease
Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)
NICE has developed a medtech innovation briefing (MIB) on Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest .
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton.
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070